Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target increased by equities researchers at Stifel Nicolaus from $92.00 to $98.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 42.03% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Citizens Jmp increased their target price on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 5th. Morgan Stanley raised their price objective on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $96.50.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $69.00 on Tuesday. The business has a 50 day simple moving average of $70.46 and a 200 day simple moving average of $64.19. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market capitalization of $3.55 billion, a PE ratio of -80.23 and a beta of 0.42. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business’s revenue was up 47.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) earnings per share. On average, sell-side analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $2,027,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $315,000. PharVision Advisers LLC bought a new stake in Mirum Pharmaceuticals in the third quarter valued at about $273,000. Virtus Advisers LLC bought a new stake in Mirum Pharmaceuticals in the third quarter valued at about $293,000. Finally, Voleon Capital Management LP acquired a new position in Mirum Pharmaceuticals in the third quarter valued at about $6,343,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.